A recently published study from Israel on booster shots of Pfizer (NYSE:PFE) and its partner BioNTech’s Covid-19 vaccine indicates that a fourth dose of the vaccine (second booster) lowered the risk of severe disease in the elderly, although protection against infection was apparently short-lived.
The U.S. recently authorized a second booster for people aged 50 and older while Israel is offering the shot for people aged 60 years or older. The data could likely encourage people to come forward and get additional protection as new Covid-19 variants emerge.
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since the end of 2016.
|S&P 500 Return||0%||-5%||102%|
|Trefis MS Portfolio Return||0%||-8%||262%|
 Month-to-date and year-to-date as of 4/7/2022
 Cumulative total returns since the end of 2016
Invest with Trefis Market Beating Portfolios